trial

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

NCTId NCT01234779
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 301 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2012-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
301 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-02
Primary completion
2012-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BitopertinOlanzapine

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizop — primary completion2012-09

Facts & assertions

4 sourced
Enrollment
301
Phase
PHASE2
Primary Completion Date
2012-09
Status
COMPLETED
relationships
The graph out of here
drug
Bitopertin
drug
Olanzapine
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication